corifollitropin alfa + gonadotropin-releasing hormone antagonist

This drug is a **combination regimen** used primarily for **controlled ovarian stimulation (COS)** in women undergoing assisted reproductive technology (ART). It combines **corifollitropin alfa**, a long-acting recombinant follicle-stimulating hormone (rFSH) analog, with a **gonadotropin-releasing hormone (GnRH) antagonist**. Corifollitropin alfa stimulates the ovaries to develop multiple follicles over a week after a single injection by mimicking the action of endogenous FSH, but with a prolonged activity due to structural modifications. The GnRH antagonist prevents premature ovulation by suppressing endogenous LH surges, allowing eggs to mature fully before retrieval. This protocol streamlines ovarian stimulation by reducing the number of injections and helps synchronize follicular development and egg retrieval in ART cycles. Corifollitropin alfa is developed using recombinant DNA technology and represents an advance in fertility treatment protocols for IVF and similar techniques[1][2][3][4][5][7][8][9].